Ophthotech Corp (OPHT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ophthotech Corp (OPHT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3461
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ophthotech Corp (Ophthotech) is a biopharmaceutical company that offers novel therapeutics to treat diseases of the back of the eye for age-related macular degeneration. The company’s products include Zimura, an anti-complemente is a central component of the complement cascade that is supposed to be used in the development of AMD. It also provides Fovista, an anti-platelet-derived growth factor (PDGF). Ophthotech offers gene therapy research programs, dry age-related macular degeneration and ophthalmic orphan programs. The company utilizes aptamer technology, a single strand of nucleic acid to targets such as PDGF, comparable to a monoclonal antibody. Its Fovista is used to inhibit abnormal new blood vessel growth associated with wet AMD. The company has its operations in New York and Princeton, the US. Ophthotech is headquartered in New York, the US.

Ophthotech Corp (OPHT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ophthotech Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ophthotech Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Ophthotech Raises US$83.3 Million In Series C Financing 11
Ophthotech Raises Funds Through Venture Financing 13
Ophthotech Raises Funds Through Venture Financing 14
Ophthotech Raises Funds Through Venture Financing 15
Partnerships 16
Ophthotech and University of Pennsylvania Enter into Agreement 16
Ophthotech Enters into Research Agreement with University of Massachusetts Medical School 17
Ophthotech Enters into Agreement with Foundation Fighting Blindness 18
Midatech Pharma Enters into Agreement with Ophthotech 19
International Drug Development Institute Partners with Ophthotech 20
Licensing Agreements 21
Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 21
Ophthotech Amends Licensing Agreement with Novartis 22
Equity Offering 24
Ophthotech Plans to Raise up to USD150 in Public Offering of Securities 24
Ophthotech Completes Public Offering Of Shares For US$60 Million 25
Ophthotech Completes IPO For US$192.3 Million 26
Ophthotech Corp – Key Competitors 27
Ophthotech Corp – Key Employees 28
Ophthotech Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Strategy And Business Planning 30
Feb 01, 2017: Ophthotech Announces Strategic Review Plan 30
Financial Announcements 31
Aug 01, 2018: Ophthotech Reports Second Quarter 2018 Financial and Operating Results 31
May 09, 2018: Ophthotech announces Q1 2018 results 33
Feb 27, 2018: Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results 35
Nov 08, 2017: Ophthotech Reports Third Quarter 2017 Financial and Operating Results 37
Jul 26, 2017: Ophthotech Reports Second Quarter 2017 Financial and Operating Results 39
Jul 26, 2017: Ophthotech Q2 net loss decreases 40
May 03, 2017: Ophthotech Reports First Quarter 2017 Financial and Operating Results 41
Feb 28, 2017: Ophthotech Reports Fourth Quarter and Full Year 2016 Financial and Operating Results 42
Corporate Communications 43
Jan 16, 2018: Ophthotech Announces Election of Jane Pritchett Henderson to Its Board of Directors 43
Apr 24, 2017: Ophthotech Announces Leadership Transition Effective July 1, 2017 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Ophthotech Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ophthotech Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ophthotech Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ophthotech Raises US$83.3 Million In Series C Financing 11
Ophthotech Raises Funds Through Venture Financing 13
Ophthotech Raises Funds Through Venture Financing 14
Ophthotech Raises Funds Through Venture Financing 15
Ophthotech and University of Pennsylvania Enter into Agreement 16
Ophthotech Enters into Research Agreement with University of Massachusetts Medical School 17
Ophthotech Enters into Agreement with Foundation Fighting Blindness 18
Midatech Pharma Enters into Agreement with Ophthotech 19
International Drug Development Institute Partners with Ophthotech 20
Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 21
Ophthotech Amends Licensing Agreement with Novartis 22
Ophthotech Plans to Raise up to USD150 in Public Offering of Securities 24
Ophthotech Completes Public Offering Of Shares For US$60 Million 25
Ophthotech Completes IPO For US$192.3 Million 26
Ophthotech Corp, Key Competitors 27
Ophthotech Corp, Key Employees 28
Ophthotech Corp, Other Locations 29

List of Figures
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Ophthotech Corp (OPHT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Edmond de Rothschild (Suisse) S.A.:企業の戦略・SWOT・財務情報
    Edmond de Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report Summary Edmond de Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • PanAust Ltd:企業の戦略・SWOT・財務分析
    PanAust Ltd - Strategy, SWOT and Corporate Finance Report Summary PanAust Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Mitsubishi International Food Ingredients, Inc.:戦略・SWOT・企業財務分析
    Mitsubishi International Food Ingredients, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi International Food Ingredients, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Kymab Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Kymab Ltd (Kymab) is a therapeutic antibody company that provides drug and vaccine development solutions. The company offers pipepline of assets in the therapeutic areas of immuno-oncology, inflammatory disease, haematology, and infectious diseases. Its pipeline products includes KY1003-Anti …
  • ET Solar Group Corporation-エネルギー分野:企業M&A・提携分析
    Summary ET Solar Group Corporation (ET Solar) is a provider of renewable energy equipment and services. The company produces a wide variety of photovoltaic (PV) modules based on global standards such as IEC, TUV, VDE, and UL. It also provides horizontally integrated project development; finance and …
  • Discovery Holdings Limited (DSY):企業の財務・戦略的SWOT分析
    Discovery Holdings Limited (DSY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • BCE Inc (BCE):企業の財務・戦略的SWOT分析
    BCE Inc (BCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Wegmans Food Markets Inc:企業の戦略的SWOT分析
    Wegmans Food Markets Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Kalle GmbH:企業の戦略的SWOT分析
    Kalle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Meera Industries Ltd (540519):企業の財務・戦略的SWOT分析
    Meera Industries Ltd (540519) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Norwegian Air Shuttle ASA:企業の戦略・SWOT・財務分析
    Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report Summary Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Syndax Pharmaceuticals Inc (SNDX):企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • PT Kalbe Farma Tbk (KLBF):製薬・医療:M&Aディール及び事業提携情報
    Summary PT Kalbe Farma Tbk (Kalbe) provides a wide range of healthcare solutions. The company undertakes the development, manufacturing and distribution of prescription pharmaceutical products, consumer health products, nutritional products and healthcare services. Its product portfolio comprises br …
  • Wesfarmers Ltd (WES)-エネルギー分野:企業M&A・提携分析
    Summary Wesfarmers Limited (Wesfarmers) is a diversified company that has business operations in retail and industrial activities. Its retail activities include supermarkets, liquor, hotels and convenience stores; department stores; home improvement and office supplies; and apparel retailing. The co …
  • Juvenile Diabetes Research Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Juvenile Diabetes Research Foundation (JDRF) is a research organization that offers funding services for type 1 diabetes. The organization conducts clinical trials for curing, preventing and treating for type 1 diabetes and its complications; and researching new drugs for patients to manage …
  • Sulzer Ltd (SUN):電力:M&Aディール及び事業提携情報
    Summary Sulzer Ltd (Sulzer) is an industrial engineering company that manufactures and supplies pump equipment. It offers mixers, compressors, agitators and aeration equipment. The company provides repair and maintenance service solutions for turbines, pumps, compressors, motors, and generators. Sul …
  • CEC Entertainment, Inc:企業の戦略・SWOT・財務情報
    CEC Entertainment, Inc - Strategy, SWOT and Corporate Finance Report Summary CEC Entertainment, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Pacific & Orient Berhad:企業の戦略・SWOT・財務情報
    Pacific & Orient Berhad - Strategy, SWOT and Corporate Finance Report Summary Pacific & Orient Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Firalis SAS:企業の製品パイプライン分析2018
    Summary Firalis SAS (Firalis) is a biotechnology company that develops biomarkers and biomarker-based diagnostic kits. The company’s biomarker products comprise recombinant proteins and calibrants, Elisa kits, and monoclonal antibodies, among others. It offers biomarker services such as flow cytomet …
  • Option NV (OPTI):企業の財務・戦略的SWOT分析
    Option NV (OPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆